Compound	Target	Selleckchem Catalogue No.	Notes
MK-2206 2HCl	AKT	S1078	Allosteric inhibitor activated by the pleckstrin homology domain
BI 2536	PLK1	S1109	Inhibits PLK1, inhibits BRD4 kinase
Sorafenib	VEGFR, RAF	S1040	Multikinase inhibitor of Raf-1, B-Raf and VEGFR-2
Staurosporine	PKC	S1421	PKC inhibitor for PKCα, PKCγ and PKCη
Ruxolitinib	JAK1/2	S1378	Kinase inhibitor
Rapamycin	mTOR	S1039	Binds FKBP12, which inhibits mTOR
Selumetinib	ERK/MEK	S1008	Non-ATP Competitive inhibitor
CHIR-99021	GSK-3α/β	S2924	ATP competitive inhibitor
Cerdulatinib	TYK2	S7634	Also targets JAK1/JAK2/JAK3/ and Syk
TG003	CLK	S7320	ATP competitive inhibitor
WZ4003	NUAK	S7317	Targets NUAK1 and NUAK2
SCH772984	ERK1/2	S7101	ATP competitive inhibitor
PD98059	MEK	S1177	Non-ATP competitive inhibitor
ML141	CDC42	S7686	Reversible non-competitive inhibitor
Enzastaurin	PKC	S1055	PKCβ selective inhibitor
BI-D1870	RSK1/2/3/4	S2843	ATP-competitive inhibitor
KN-93 Phosphate	CaMKII	S7423	No effect on APK, PKC, MLCK or Ca2+-PDE
CID755673	PKD1/2/3	S7188	Cell-active pan-PKD1/2/3 inhibitor
FR 180204	ERK	S7524	ATP-competitive inhibitor
Alisertib	AURKA	S1133	>200-fold higher selectivity for Aurora A than Aurora B
LDC000067	CDK9	S7461	>227-fold selectivity over CDK2/1/4/6/7
SNS-032	CDK2/7/9	S1145	Reversible inhbitor
H 89 2HCl	PKA	S1582	Also inhibits CaMKII, CK1, MYLK
SB203580	p38 MAPK	S1076	Also blocks AKT
BAY 80-6946	PI3K	S2802	Pan-class I PI3K inhibitor
HTH-01-015	NUAK1	S7318	Selective for NUAK1 over NUAK2

Supplemental Table 1. Compounds that did not block telomere elongation by telomerase overexpression.



Supplemental Figure S1. The Southern blots shown in Figure 4 were analyzed to determine peak density in each lane using ImageQuant software as described in the methods. The median telomere length for each sample is marked with a red bar on each Southern blot.